You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

HYDROCORTISONE ACETATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Hydrocortisone Acetate patents expire, and what generic alternatives are available?

Hydrocortisone Acetate is a drug marketed by Cenci, Ferndale Labs, Parke Davis, Purepac Pharm, Akorn, Bel Mar, Watson Labs, Fera Pharms, X Gen Pharms, and Genus. and is included in thirteen NDAs.

The generic ingredient in HYDROCORTISONE ACETATE is hydrocortisone acetate; pramoxine hydrochloride. There are sixty-seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the hydrocortisone acetate; pramoxine hydrochloride profile page.

Summary for HYDROCORTISONE ACETATE
Drug patent expirations by year for HYDROCORTISONE ACETATE
Recent Clinical Trials for HYDROCORTISONE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Feinstein Institute for Medical ResearchPhase 2
University of Texas Southwestern Medical CenterPhase 2
National Institutes of Health Clinical Center (CC)Phase 2

See all HYDROCORTISONE ACETATE clinical trials

US Patents and Regulatory Information for HYDROCORTISONE ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cenci HYDROCORTISONE ACETATE hydrocortisone acetate CREAM;TOPICAL 080419-001 Jan 25, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Akorn HYDROCORTISONE ACETATE hydrocortisone acetate INJECTABLE;INJECTION 009637-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Purepac Pharm HYDROCORTISONE ACETATE hydrocortisone acetate CREAM;TOPICAL 086050-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs HYDROCORTISONE ACETATE hydrocortisone acetate INJECTABLE;INJECTION 083759-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Bel Mar HYDROCORTISONE ACETATE hydrocortisone acetate INJECTABLE;INJECTION 083739-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Genus HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1% hydrocortisone acetate; pramoxine hydrochloride AEROSOL, METERED;TOPICAL 089440-001 May 17, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Mallinckrodt
Moodys
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.